CASI Pharmaceuticals (CASI) announced that China National Medical Products Administration has approved a Clinical Trial Application to conduct a Phase 1 /2 clinical trial for CID-103 in adults with chronic active renal allograft antibody-mediated rejection. The Phase 1 / 2 clinical trial is a dose-ranging and safety study evaluating the tolerability and efficacy of CID-103 in patients with renal allograft AMR.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CASI:
- CASI Pharmaceuticals Closes Second Tranche of US$20 Million Convertible Note Financing
- Casi Pharmaceuticals announces results from Phase 1 study of CID-103
- CASI Pharmaceuticals Closes First US$5 Million Tranche of Convertible Note Financing
- CASI Pharmaceuticals Wins Nasdaq Listing Extension to February 2026
- CASI Pharmaceuticals Secures $20 Million for Renal AMR Study